UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | | --- | | Not applicable | (State or other jurisdiction ...

Recent Highlights and Accomplishments for Lifeward U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference cal ...

Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global lead ...

Core Viewpoint - Lifeward Ltd. has launched the ReWalk 7 Personal Exoskeleton in the U.S., enhancing assistive technology for individuals with spinal cord injuries, showcasing the company's leadership and technological advancements in the industry [1][2][5]. Product Launch and Market Impact - The ReWalk 7 received FDA clearance in March 2025 and follows the ReWalk 6.0 system, which improved user capabilities for navigating stairs and curbs [2]. - The introduction of a Medicare reimbursement pathway in 2024 has facilitated broader market access for the ReWalk 7, supporting Lifeward's mission to empower the spinal cord injury community [2][5]. Technological Enhancements - The ReWalk 7 features cloud connectivity for data-driven updates, two customizable walking speeds, and a new crutch control unit for enhanced user control [7]. - Complementary devices, including a wrist control smartwatch and a mobile application, simplify mode selection and progress tracking, integrating the device into daily routines [7]. User-Centric Development - Lifeward collaborated with over two dozen end users and physical therapists to gather feedback, leading to improvements in training efficiency and safety [9]. - The development process included the introduction of a therapist handheld device for better session control, resulting in a device that enhances user confidence and control [9]. Financial Performance - Following the launch announcement, LFWD's shares increased by 1.4% on April 15, although the company has experienced an 18% decline in shares year-to-date, compared to an 11.1% decline in the industry and an 8.4% drop in the S&P 500 Index [4].

Smarter, smoother, more powerful. Learn more at golifeward.com/rewalk7 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in inn ...

Lifeward Ltd. (LFWD) recently announced that it has received FDA 510(k) clearance for its latest innovation, the ReWalk 7 Exoskeleton. This next-generation wearable device is designed to help individuals with spinal cord injuries (SCI) stand and walk, featuring new and enhanced functionalities aimed at improving user experience and mobility outcomes.The FDA clearance marks a significant milestone for Lifeward, reinforcing its leadership in the medical exoskeleton market. With prior regulatory and reimbursem ...

Core Insights - Lifeward Ltd. has received 510(k) FDA clearance for its latest personal exoskeleton device, the ReWalk 7, which is designed for individuals with spinal cord injury (SCI) [1][2] - The ReWalk 7 features new enhancements and upgrades, continuing Lifeward's commitment to providing advanced exoskeleton technology [2] - The company plans to begin sales of the ReWalk 7 in the United States as soon as it becomes available [3] Company Developments - Lifeward has a history of innovation, having previously received FDA clearance for the ReWalk 6.0 in 2023, which allowed use on stairs and curbs, and a national reimbursement policy from CMS in 2024 for eligible beneficiaries [2] - The company was the first to receive FDA clearance for an exoskeleton medical device for individuals with SCI in 2014 [2] - Lifeward's mission is to drive innovation in medical technology to improve the lives of individuals with physical limitations or disabilities [3] Product Portfolio - Lifeward's product offerings include the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, all aimed at enhancing rehabilitation and recovery [3]

Lifeward (LFWD) Q4 2024 Earnings Call March 07, 2025 04:52 PM ET Company Participants Mike Lawless - CFOLarry Jasinski - CEOBen Haynor - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech AnalystRamakanth Swayampakula - Managing Director & Senior Research Analyst Operator Good day, and welcome to the Life Learning Fourth Quarter twenty twenty four Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be ...

Lifeward Ltd. (NASDAQ:LFWD) Q4 2024 Earnings Conference Call March 7, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw & Company Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Lifeward Inc. Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen only mode [Operator Instructions]. Please note, today's event is be ...